49 results on '"Marco‐Marín, Clara"'
Search Results
2. Discovery of 3H-pyrrolo[2,3-c]quinolines with activity against Mycobacterium tuberculosis by allosteric inhibition of the glutamate-5-kinase enzyme
- Author
-
Panciera, Michele, Lence, Emilio, Rodríguez, Ángela, Gracia, Begoña, Aínsa, José A., Marco-Marín, Clara, Rubio, Vicente, Duarte Correia, Carlos Roque, and González-Bello, Concepción
- Published
- 2022
- Full Text
- View/download PDF
3. Genetic Heterogeneity Underlying Phenotypes with Early-Onset Cerebellar Atrophy
- Author
-
Martínez-Rubio, Dolores, primary, Hinarejos, Isabel, additional, Argente-Escrig, Herminia, additional, Marco-Marín, Clara, additional, Lozano, María Ana, additional, Gorría-Redondo, Nerea, additional, Lupo, Vincenzo, additional, Martí-Carrera, Itxaso, additional, Miranda, Concepción, additional, Vázquez-López, María, additional, García-Pérez, Asunción, additional, Marco-Hernández, Ana Victoria, additional, Tomás-Vila, Miguel, additional, Aguilera-Albesa, Sergio, additional, and Espinós, Carmen, additional
- Published
- 2023
- Full Text
- View/download PDF
4. C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein
- Author
-
Gargantilla, Marta, primary, Francés, Clara, additional, Adhav, Anmol, additional, Forcada-Nadal, Alicia, additional, Martínez-Gualda, Belén, additional, Martí-Marí, Olaia, additional, López-Redondo, María Luisa, additional, Melero, Roberto, additional, Marco-Marín, Clara, additional, Gougeard, Nadine, additional, Espinosa, Carolina, additional, Rubio-del-Campo, Antonio, additional, Ruiz-Partida, Rafael, additional, Hernández-Sierra, María del Pilar, additional, Villamayor-Belinchón, Laura, additional, Bravo, Jerónimo, additional, Llacer, José-Luis, additional, Marina, Alberto, additional, Rubio, Vicente, additional, San-Félix, Ana, additional, Geller, Ron, additional, and Pérez-Pérez, María-Jesús, additional
- Published
- 2023
- Full Text
- View/download PDF
5. A newly distal hereditary motor neuropathy caused by a rare AIFM1 mutation
- Author
-
Sancho, Paula, Sánchez-Monteagudo, Ana, Collado, Antonio, Marco-Marín, Clara, Domínguez-González, Cristina, Camacho, Ana, Knecht, Erwin, Espinós, Carmen, and Lupo, Vincenzo
- Published
- 2017
- Full Text
- View/download PDF
6. Patología molecular y cristalografía de rayos X arrojan nueva luz sobre la deficiencia de la Carbamil Fosfato Sintetasa 1 humana (HuCPS1)
- Author
-
Gougeard, Nadine, Díez-Fernández, Carmen, Cima, Sergio de, Polo, Luis Mariano, Marco-Marín, Clara, Fita, Ignacio, and Rubio, Vicente
- Abstract
Trabajo presentado en la Jornada día Mundial de las Enfermedades Raras, celebrado en Alicante (España) el 02 de marzo de 2023.
- Published
- 2023
7. Mutations, Genes, and Phenotypes Related to Movement Disorders and Ataxias
- Author
-
Martínez-Rubio, Dolores, primary, Hinarejos, Isabel, additional, Sancho, Paula, additional, Gorría-Redondo, Nerea, additional, Bernadó-Fonz, Raquel, additional, Tello, Cristina, additional, Marco-Marín, Clara, additional, Martí-Carrera, Itxaso, additional, Martínez-González, María Jesús, additional, García-Ribes, Ainhoa, additional, Baviera-Muñoz, Raquel, additional, Sastre-Bataller, Isabel, additional, Martínez-Torres, Irene, additional, Duat-Rodríguez, Anna, additional, Janeiro, Patrícia, additional, Moreno, Esther, additional, Pías-Peleteiro, Leticia, additional, Gordo, Mar O’Callaghan, additional, Ruiz-Gómez, Ángeles, additional, Muñoz, Esteban, additional, Martí, Maria Josep, additional, Sánchez-Monteagudo, Ana, additional, Fuster, Candela, additional, Andrés-Bordería, Amparo, additional, Pons, Roser Maria, additional, Jesús-Maestre, Silvia, additional, Mir, Pablo, additional, Lupo, Vincenzo, additional, Pérez-Dueñas, Belén, additional, Darling, Alejandra, additional, Aguilera-Albesa, Sergio, additional, and Espinós, Carmen, additional
- Published
- 2022
- Full Text
- View/download PDF
8. CryoEM structures of the SARS-CoV-2 spike bound to antivirals
- Author
-
López-Redondo, María Luisa, Marco-Marín, Clara, Gougeard, Nadine, Forcada-Nadal, Alicia, Adhav, Anmol, Zamora-Caballero, Sara, Melero, Roberto, Hurtado, Ramón, Peréz-Pérez, María-Jesús, Bravo Sicilia, Jerónimo, Rubio, Vicente, Marina, Alberto, and Llacer Guerri, Jose Luis
- Abstract
(Póster 63) Background: Single-particle cryoelectron microscopy (cryoEM) has played a key role in the fight against COVID-19. The molecular mechanisms for the action of some of the currently approved drugs targeting the SARS-CoV-2 RNA-dependent RNA polymerase, the fast developments of the current available vaccines and antibody therapies are examples of the impact of the knowledge gained from the cryoEM structures of SARS-CoV-2 proteins in complex with proteins (ACE2 or antibodies/nanobodies) or small compounds. Our aim is to use this technology to understand structurally how certain antiviral compounds and proteins targeting the spike may inhibit viral entry. Methods: 1) Production of wild-type and mutated spike and ACE2 proteins using baculovirus/insect cells. 2) Spike binding kinetics: protein-protein and protein-small compound interactions measured by BLI Biolayer interferometry (BLI) and/or microscale Thermophoresis (MST). 3) Buffer optimization for cryoEM grid preparation of spike variants by thermal shift assays and negative-staining electron microscopy (NSEM). These techniques are also used to adjust the molar ratio of spike:ACE2 and spike:small-compound complexes. 4) Structural characterization by cryoEM. Results: At IBV-CSIC we have created a pipeline for the production and characterization of several spike variants and ACE2 decoys. While this pipeline is described in detail in other oral/poster communications, this communication is centered around one of the pillars within this pipeline; the structural characterization of possible drug candidates bound to the SARS-CoV-2 spike by cryoEM. In this way, we have successfully solved structures of the spike bound to: A) protein inhibitors as ACE2 decoys; B) a small inhibitory compound; C) mixtures of proteins and small-compound (nanobody-heparan derivative) working cooperatively as inhibitors. These protein/drug candidates were previously selected based on the results obtained in our interactomics platform, whereas their concentration and the buffer conditions for cryoEM grids preparation were established based on thermal shift assays and NSEM. Conclusion: CryoEM is a powerful tool to directly visualize the effect caused by a potential drug on a protein target. In a short period of time we have developed this technique in our institute to be applied to the SARS-CoV-2 spike protein, not only to obtain high-resolution structures of SARS- CoV-2 spike variants of concern (see WP4) but also to obtain the structures of complexes of the spike with various inhibitory compounds of very different nature.
- Published
- 2022
9. Use of an interactomics pipeline to assess the potential of new antivirals against SARS-CoV-2
- Author
-
Marina Moreno, Alberto, Forcada-Nadal, Alicia, Adhav, Anmol, Rubio del Campo, Antonio, Sanz-Frasquet, Carla, Marco-Marín, Clara, Bravo Sicilia, Jerónimo, Llacer Guerri, Jose Luis, Peréz-Pérez, María-Jesús, López-Redondo, María Luisa, Hernández-Sierra, María Pilar, Gargantilla, Marta, Ruiz Partida, Rafa, Gozalbo-Rovira, Roberto, Ramón-Maiques, Santiago, Zamora Caballero, Sara, Martín Santamaría, Sonsoles, and Rubio, Vicente
- Abstract
(Póster 80) Background: In late 2019 SARS-CoV-2 infection appeared in China, becoming a pandemic in 2020. The scientific community reacted rapidly, characterizing the viral genome and its encoded proteins, aiming at interfering with viral spreading with vaccines and antivirals. The receptor binding domain (RBD) of the viral spike (S) protein plays a key role in cell entry of the virus. It interacts with the cellular receptor for SARS-CoV-2, the membrane-bound human Angiotensin Converting Ectoenzyme 2 (ACE2). With the goal of monitoring interference with this interaction by potential antiviral drugs, we have set up at the Institute for Biomedicine of Valencia (IBV-CSIC) an interactomics pipeline targeting the initial step of viral entry. Methods: For the production part of the pipeline (pure RBD/Spike variants and soluble ACE2), see parallel poster. These proteins allowed monitoring of the RBD/Spike-ACE2 interaction in presence or absence of potential inhibitors. Thermal shift assays (thermofluor) were used for initial detection of compound binding at different ligand/protein ratios and media conditions (pH, buffers, chaotropic agents). Next, binding affinity and on/off kinetics were characterized using Biolayer interferometry (BLI), Surface plasmon resonance (SPR), Microscale Thermophoresis (MST) and/or Isothermal titration calorimetry (ITC). For protein-protein interactions, we mostly used BLI or SPR, whereas for proteinsmall compound analysis MST was generally best. Protein aggregation-dissociation was monitored by size exclusion chromatography with multiangle light scattering (SEC-MALS). Results: Candidates proven by thermal shift assays to bind to RBD/spike protein without affecting the integrity of these proteins were subjected to quantitative affinity measurements. We successfully demonstrated that BLI, SPR and MST can be used to follow the interactions between SARS-CoV- 2 proteins and the putative drug candidates, as well as to monitor the interference with Spike-Ace2 binding of potential drug candidates. While BLI and SPR displayed reproducible results in the measurement of protein-protein interaction (applied to soluble ACE2 used as a decoy), they were less suitable for measuring the binding of small molecules. The fact that most small compounds were only soluble in organic solvents made difficult to obtain a low signal/noise while using BLI, necessary for the assessment of the binding. We overcame that problem by using MST. After dilution of the compounds to the final experimental concentrations, the technique could detect a significant binding signal enough to calculate binding parameters. MST also allowed to measure the degree of interference that each compound was having on RBD/Spike-ACE2 interaction. The pipeline has been customized and validated with compounds of very different nature provided by different groups belonging to the PTI and other external laboratories, as well as with different Ace2 decoys designed at the IBV. Conclusions: The interactomics platform at the IBV has been used to successfully develop two different antiviral approaches in order to fight COVID-19. It has allowed technical specialization of the staff as well as the development, in a very short period of time, of two ambitious projects. We have demonstrated that we can perform interactomic characterization for challenging projects as well as provide information about binding of antivirals to potential new SARS-CoV-2 variants of concern.
- Published
- 2022
10. CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative
- Author
-
Luque, Juan M., Mendes, Ingrid, Gómez, Beatriz, Morte, Beatriz, Heredia, Miguel, Lopez Herreras, Enrique, Corrochano, Virginia, Bueren, Juan, Gallano, Pia, Artuch, Rafael, Fillat, Cristina, Pérez-Jurado, Luis A., Montoliu, Lluís, Carracedo, Angel, Millán, José M., Webb, Susan M., Palau, Francesc, CIBERER Network, Lapunzina, Pablo, Albiñana, Virginia, Arjona, Emilia, Bernabéu, Carmelo, Botella, Luisa María, Pinto, Sheila, Rodríguez de Córdoba, Santiago, Ruiz, Ángela, Antiñolo, Guillermo, Borrego, Salud, Bravo-Gil, Nereida, González-del Pozo, María, Méndez-Vidal, Cristina, Arbones, Maria L., Caparrós-Martín, José Antonio, Cediel, Rafael, Contreras, Julio, Estañ, María Cristina, Guerrero-López, Rosa, Jiménez-Estrada, Juan Andrés, Manguan-García, Cristina, Murillo-Cuesta, Silvia, Palencia-Campos, Adrián, Perona Abellón, Rosario, Rivera-Barahona, Ana, Rodríguez de la Rosa, Lourdes, Ruiz-Pérez, Victor L., Sastre, Leandro, Valencia, María, Varela-Nieto, Isabel, Cervera, Javier, Cima, Sergio de, Gougeard, Nadine, Llácer, José Luis, Marco-Marín, Clara, Marina, Alberto, Mollá, Belén, Moreno-Estellés, Mireia, Pérez-Jiménez, Eva, Rubio, Vicente, Sanz, Pascual, Cortés-Rodríguez, Ana, Navas, Plácido, Sánchez Cuesta, Ana María, Santos-Ocaña, Carlos, Fraga, Mario F., Nieto, M. Ángela, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Marina, Alberto, Sanz, Pascual, Rubio, Vicente, and Llácer, José L.
- Subjects
Biomedical Research ,Epidemiology ,Novel genes ,Research network ,New therapeutic approaches ,Rare diseases ,Rare Diseases ,Diagnòstic ,Diagnosis ,Genetics ,Humans ,Malalties rares ,Epidemiologia ,Genètica ,Genetics (clinical) - Abstract
13 páginas,1 figura, 3 tablas, 1 apéndice. Se extraen los autores pertenecientes a The CIBERER network que trabajan en Centros del CSIC del Appendix A, CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research., This study has been funded by Instituto de Salud Carlos III (ISCIII) and Spanish Ministry of Science and Innovation
- Published
- 2022
11. Protein misfolding and clearance in the pathogenesis of a new infantile onset ataxia caused by mutations in PRDX3
- Author
-
Martínez-Rubio, Dolores, primary, Rodríguez-Prieto, Ángela, additional, Sancho, Paula, additional, Navarro-González, Carmen, additional, Gorría-Redondo, Nerea, additional, Miquel-Leal, Javier, additional, Marco-Marín, Clara, additional, Jenkins, Alison, additional, Soriano-Navarro, Mario, additional, Hernández, Alberto, additional, Pérez-Dueñas, Belén, additional, Fazzari, Pietro, additional, Aguilera-Albesa, Sergio, additional, and Espinós, Carmen, additional
- Published
- 2022
- Full Text
- View/download PDF
12. CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative
- Author
-
Luque, Juan, Mendes, Ingrid, Gómez, Beatriz, Morte, Beatriz, de Heredia, Miguel, Lopez Herreras, Enrique, Corrochano, Virginia, Bueren, Juan, Gallano, Pia, Artuch, Rafael, Fillat, Cristina, Pérez-Jurado, Luis A., Montoliu, Lluís, Carracedo, Angel, Millan, Jose M., Webb, Susan M., Palau, Francesc, CIBERER Network, Lapunzina, Pablo, Albiñana, Virginia, Arjona, Emilia, Bernabéu, Carmelo, Botella, Luisa M., Pinto, Sheila, Rodríguez de Córdoba, Santiago, Ruiz, Ángela, Antiñolo, Guillermo, Borrego, Salud, Bravo-Gil, Nereida, González-del Pozo, María, Méndez-Vidal, Cristina, Arbones, Maria L., Caparrós-Martín, José Antonio, Cediel, Rafael, Contreras, Julio, Estañ, María Cristina, Guerrero, Rosa, Jiménez-Estrada, Juan Andrés, Manguán García, Cristina, Murillo-Cuesta, Silvia, Palencia-Campos, Adrián, Perona, Rosario, Rivera-Barahona, Ana, Rodríguez de la Rosa, Lourdes, Ruiz-Pérez, Victor L., Sastre, Leandro, Valencia, María, Varela-Nieto, Isabel, Cervera, Javier, Cima, Sergio de, Gougeard, Nadine, Heredia, Miguel, Llácer, José Luis, Marco-Marín, Clara, Marina, Alberto, Mollá, Belén, Moreno, Mireia, Pérez-Jiménez, Eva, Rubio, Vicente, Sanz, Pascual, Cortés-Rodríguez, Ana, Navas, Plácido, Sánchez Cuesta, Ana María, Santos-Ocaña, Carlos, Fraga, Mario F., Nieto, M. Ángela, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Marina, Alberto [0000-0002-1334-5273], Sanz, Pascual [0000-0002-2399-4103], Rubio, Vicente [0000-0001-8124-1196], and Llácer, José L. [0000-0001-5304-1795]
- Subjects
Novel genes ,Genetics ,Research network ,New therapeutic approaches ,Rare diseases - Abstract
13 páginas,1 figura, 3 tablas, 1 apéndice. Se extraen los autores pertenecientes a The CIBERER network que trabajan en Centros del CSIC del Appendix A CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research. This study has been funded by Instituto de Salud Carlos III (ISCIII) and Spanish Ministry of Science and Innovation
- Published
- 2022
13. The role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, The IBV-Covid19-Pipeline, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Abstract
Resumen del trabajo presentado a las II Jornadas Científicas PTI + Salud Global, celebradas los días 5 y 6 de octubre de 2022 en el Auditorio Santiago Grisolía de Valencia (España).
- Published
- 2022
14. A novel TRMT5 mutation causes a complex inherited neuropathy syndrome: the role of nerve pathology in defining a demyelinating neuropathy
- Author
-
Argente‐Escrig, Herminia, primary, Vílchez, Juan Jesus, additional, Frasquet, Marina, additional, Muelas, Nuria, additional, Azorín, Inmaculada, additional, Vílchez, Roger, additional, Millet‐Sancho, Elvira, additional, Pitarch, Inmaculada, additional, Tomás‐Vila, Miguel, additional, Vázquez‐Costa, Juan F., additional, Mas‐Estellés, Fernando, additional, Marco‐Marín, Clara, additional, Espinós, Carmen, additional, Serrano‐Lorenzo, Pablo, additional, Martin, Miguel A., additional, Lupo, Vincenzo, additional, and Sevilla, Teresa, additional
- Published
- 2022
- Full Text
- View/download PDF
15. The Crystal Structure of the Complex of ${\rm P}_{{\rm II}}$ and Acetylglutamate Kinase Reveals How ${\rm P}_{{\rm II}}$ Controls the Storage of Nitrogen as Arginine
- Author
-
Llácer, José L., Contreras, Asunción, Forchhammer, Karl, Marco-Marín, Clara, Gil-Ortiz, Fernando, Maldonado, Rafael, Fita, Ignacio, and Rubio, Vicente
- Published
- 2007
- Full Text
- View/download PDF
16. Understanding N-Acetyl-L-Glutamate Synthase Deficiency: Mutational Spectrum, Impact of Clinical Mutations on Enzyme Functionality, and Structural Considerations
- Author
-
Sancho-Vaello, Enea, Marco-Marín, Clara, Gougeard, Nadine, Fernández-Murga, Leonor, Rüfenacht, Véronique, Mustedanagic, Merima, Rubio, Vicente, and Häberle, Johannes
- Published
- 2016
- Full Text
- View/download PDF
17. ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism
- Author
-
Panza, Emanuele, Escamilla-Honrubia, Juan M., Marco-Marín, Clara, Gougeard, Nadine, De Michele, Giuseppe, Morra, Vincenzo Brescia, Liguori, Rocco, Salviati, Leonardo, Donati, Maria Alice, Cusano, Roberto, Pippucci, Tommaso, Ravazzolo, Roberto, Németh, Andrea H., Smithson, Sarah, Davies, Sally, Hurst, Jane A., Bordo, Domenico, Rubio, Vicente, and Seri, Marco
- Published
- 2016
- Full Text
- View/download PDF
18. Δ1 -Pyrroline-5-carboxylate synthetase (P5CS) deficiency: An emergent multifaceted urea cycle-related disorder
- Author
-
Marco-Marín, Clara, Escamilla-Honrubia, Juan M, Llácer, José L, Seri, Marco, Panza, Emanuele, Rubio, Vicente, Marco-Marín, Clara, Escamilla-Honrubia, Juan M, Llácer, José L, Seri, Marco, Panza, Emanuele, and Rubio, Vicente
- Subjects
ALDH18A1 gene-related disorders. Cutis laxa type III. Hereditary spastic paraplegia type 9. ARCL3A. ADCL3. SPG9A. SPG9B - Abstract
The bifunctional homooligomeric enzyme Δ1 -pyrroline-5-carboxylate synthetase (P5CS) and its encoding gene ALDH18A1 were associated with disease in 1998. Two siblings who presented paradoxical hyperammonemia (alleviated by protein), mental disability, short stature, cataracts, cutis laxa and joint laxity, were found to carry biallelic ALDH18A1 mutations. They showed biochemical indications of decreased ornithine/proline synthesis, agreeing with the role of P5CS in the biosynthesis of these amino acids. Of 32 patients reported with this neurocutaneous syndrome, 21 familial ones hosted homozygous or compound heterozygous ALDH18A1 mutations, while 11 sporadic ones carried de novo heterozygous ALDH18A1 mutations. In 2015-2016 an upper motor neuron syndrome (spastic paraparesis/paraplegia SPG9) complicated with some traits of the neurocutaneous syndrome, although without report of cutis laxa, joint laxity or herniae, was associated with monoallelic or biallelic ALDH18A1 mutations with, respectively, dominant and recessive inheritance. Of fifty SPG9 patients reported, 14 and 36 (34/2 familial/sporadic) carried, respectively, biallelic and monoallelic mutations. Thus, two neurocutaneous syndromes (recessive and dominant cutis laxa 3, abbreviated ARCL3A and ADCL3, respectively) and two SPG9 syndromes (recessive SPG9B and dominant SPG9A) are caused by essentially different spectra of ALDH18A1 mutations. On the bases of the clinical data (including our own prior patients' reports), the ALDH18A1 mutations spectra, and our knowledge on the P5CS protein, we conclude that the four syndromes share the same pathogenic mechanisms based on decreased P5CS function. Thus, these syndromes represent a continuum of increasing severity (SPG9A
- Published
- 2020
19. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, Ruiz-Rodriguez, Paula, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jeronimo, Rubio, Vicente, and Marina, Alberto
- Subjects
- *
SARS-CoV-2 , *GENETIC mutation , *VACCINE effectiveness , *VIRAL mutation , *VIRAL genomes , *COVID-19 , *AVIAN influenza - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness. Author summary: Since early 2020, the trajectory of the COVID-19 pandemic has mostly been shaped by the appearance of novel variants of the SARS-CoV-2 virus. Accordingly, much of the scientific effort has been directed toward the question of explaining, understanding, and predicting the evolutionary fate of individual mutations in the viral genome. In this article, we focus on A222V, a particular mutation in the Spike protein that emerged in Spain in mid-2020 and reappeared independently in the AY.4.2 subvariant of Delta one year later. As reemerging mutations often indicate an evolutionary advantage, we explored potential mechanisms linking A222V to biologically relevant outcomes. Using serological, functional, structural, and computational approaches, we identified key molecular-level differences conferred by A222V that potentially explain its repeated emergence in different genetic backgrounds. Our results point to subtle changes in the dynamic behavior of the receptor-binding domain in the binding-competent "up" conformation, ones that affect receptor binding itself, but can also act synergistically with other mutations by changing the accessibility of key residues involved in molecular recognition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine
- Author
-
Martinelli, Diego, Häberle, Johannes, Rubio, Vicente, Giunta, Cecilia, Hausser, Ingrid, Carrozzo, Rosalba, Gougeard, Nadine, Marco-Marín, Clara, Goffredo, Bianca M., Meschini, Maria Chiara, Bevivino, Elsa, Boenzi, Sara, Colafati, Giovanna Stefania, Brancati, Francesco, Baumgartner, Matthias R., and Dionisi-Vici, Carlo
- Published
- 2012
- Full Text
- View/download PDF
21. Congenital hypomyelinating neuropathy due to a novel MPZ mutation
- Author
-
Sevilla, Teresa, Lupo, Vincenzo, Sivera, Rafael, Marco-Marín, Clara, Martínez-Rubio, Dolores, Rivas, Eloy, Hernández, Arturo, Palau, Francesc, and Espinós, Carmen
- Published
- 2011
- Full Text
- View/download PDF
22. Functional and structural characterization of PII‐like protein CutA does not support involvement in heavy metal tolerance and hints at a small‐molecule carrying/signaling role
- Author
-
Selim, Khaled A., primary, Tremiño, Lorena, additional, Marco‐Marín, Clara, additional, Alva, Vikram, additional, Espinosa, Javier, additional, Contreras, Asunción, additional, Hartmann, Marcus D., additional, Forchhammer, Karl, additional, and Rubio, Vicente, additional
- Published
- 2020
- Full Text
- View/download PDF
23. Δ 1 ‐Pyrroline‐5‐carboxylate synthetase deficiency: An emergent multifaceted urea cycle‐related disorder
- Author
-
Marco‐Marín, Clara, primary, Escamilla‐Honrubia, Juan M., additional, Llácer, José L., additional, Seri, Marco, additional, Panza, Emanuele, additional, and Rubio, Vicente, additional
- Published
- 2020
- Full Text
- View/download PDF
24. Nitrogen storage regulation by PII protein: lessons learned from taxonomic outliers
- Author
-
Rubio, Vicente, primary, Marco‐Marín, Clara, additional, and Llácer, José Luis, additional
- Published
- 2020
- Full Text
- View/download PDF
25. The PII-NAGK-PipX-NtcA Regulatory Axis of Cyanobacteria: A Tale of Changing Partners, Allosteric Effectors and Non-covalent Interactions
- Author
-
Forcada-Nadal, Alicia, primary, Llácer, José Luis, additional, Contreras, Asunción, additional, Marco-Marín, Clara, additional, and Rubio, Vicente, additional
- Published
- 2018
- Full Text
- View/download PDF
26. Functional and structural characterization of PII‐like protein CutA does not support involvement in heavy metal tolerance and hints at a small‐molecule carrying/signaling role.
- Author
-
Selim, Khaled A., Tremiño, Lorena, Marco‐Marín, Clara, Alva, Vikram, Espinosa, Javier, Contreras, Asunción, Hartmann, Marcus D., Forchhammer, Karl, and Rubio, Vicente
- Subjects
SYNECHOCOCCUS elongatus ,METAL coating ,SMALL molecules ,PROTEINS ,HEAVY metals - Abstract
The PII‐like protein CutA is annotated as being involved in Cu2+ tolerance, based on analysis of Escherichia coli mutants. However, the precise cellular function of CutA remains unclear. Our bioinformatic analysis reveals that CutA proteins are universally distributed across all domains of life. Based on sequence‐based clustering, we chose representative cyanobacterial CutA proteins for physiological, biochemical, and structural characterization and examined their involvement in heavy metal tolerance, by generating CutA mutants in filamentous Nostoc sp. and in unicellular Synechococcus elongatus. However, we were unable to find any involvement of cyanobacterial CutA in metal tolerance under various conditions. This prompted us to re‐examine experimentally the role of CutA in protecting E. coli from Cu2+. Since we found no effect on copper tolerance, we conclude that CutA plays a different role that is not involved in metal protection. We resolved high‐resolution CutA structures from Nostoc and S. elongatus. Similarly to their counterpart from E. coli and to canonical PII proteins, cyanobacterial CutA proteins are trimeric in solution and in crystal structure; however, no binding affinity for small signaling molecules or for Cu2+ could be detected. The clefts between the CutA subunits, corresponding to the binding pockets of PII proteins, are formed by conserved aromatic and charged residues, suggesting a conserved binding/signaling function for CutA. In fact, we find binding of organic Bis‐Tris/MES molecules in CutA crystal structures, revealing a strong tendency of these pockets to accommodate cargo. This highlights the need to search for the potential physiological ligands and for their signaling functions upon binding to CutA. Databases: Structural data are available in Protein Data Bank (PDB) under the accession numbers 6GDU, 6GDV, 6GDW, 6GDX, 6T76, and 6T7E. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Δ1‐Pyrroline‐5‐carboxylate synthetase deficiency: An emergent multifaceted urea cycle‐related disorder.
- Author
-
Marco‐Marín, Clara, Escamilla‐Honrubia, Juan M., Llácer, José L., Seri, Marco, Panza, Emanuele, and Rubio, Vicente
- Abstract
The bifunctional homooligomeric enzyme Δ1‐pyrroline‐5‐carboxylate synthetase (P5CS) and its encoding gene ALDH18A1 were associated with disease in 1998. Two siblings who presented paradoxical hyperammonemia (alleviated by protein), mental disability, short stature, cataracts, cutis laxa, and joint laxity, were found to carry biallelic ALDH18A1 mutations. They showed biochemical indications of decreased ornithine/proline synthesis, agreeing with the role of P5CS in the biosynthesis of these amino acids. Of 32 patients reported with this neurocutaneous syndrome, 21 familial ones hosted homozygous or compound heterozygous ALDH18A1 mutations, while 11 sporadic ones carried de novo heterozygous ALDH18A1 mutations. In 2015 to 2016, an upper motor neuron syndrome (spastic paraparesis/paraplegia SPG9) complicated with some traits of the neurocutaneous syndrome, although without report of cutis laxa, joint laxity, or herniae, was associated with monoallelic or biallelic ALDH18A1 mutations with, respectively, dominant and recessive inheritance. Of 50 SPG9 patients reported, 14 and 36 (34/2 familial/sporadic) carried, respectively, biallelic and monoallelic mutations. Thus, two neurocutaneous syndromes (recessive and dominant cutis laxa 3, abbreviated ARCL3A and ADCL3, respectively) and two SPG9 syndromes (recessive SPG9B and dominant SPG9A) are caused by essentially different spectra of ALDH18A1 mutations. On the bases of the clinical data (including our own prior patients' reports), the ALDH18A1 mutations spectra, and our knowledge on the P5CS protein, we conclude that the four syndromes share the same pathogenic mechanisms based on decreased P5CS function. Thus, these syndromes represent a continuum of increasing severity (SPG9A < SPG9B < ADCL3 ≤ ARCL3A) of the same disease, P5CS deficiency, in which the dominant mutations cause loss‐of‐function by dominant‐negative mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Deciphering the mechanism by which 1-pyrrolin-5-carboxylate synthetase defects associate with dominant and recessive human pathologies
- Author
-
Escamilla Honrubia, Juan Manuel, Marco-Marín, Clara, Gougeard, Nadine, Rubio, Vicente, and Ministerio de Economía y Competitividad (España)
- Abstract
Póster original presentado al XXXVIII Congreso de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM), celebrado en Valencia, 7-10 de septiembre de 2015, Δ1-Pyrrolin-5-carboxylate synthetase (P5CS) is a bifunctional enzyme that catalyzesthe first two steps of ornithine/proline biosynthesis in plants and animals. It is composed of an N-terminal glutamate-5-kinase (G5K) domain that uses ATP to phosphorylate the γ-carboxylate of glutamate, and of a C-terminal L-glutamyl-5-phosphate reductase (G5PR) domain that reductively dephosphorylates L-glutamyl-5-phosphate to L-glutamate-5-semialdehyde. This compound spontaneously cyclizes to Δ1-pyrrolin-5-carboxylate, thus being a precursor of both ornithine and proline. Human P5CS deficiency was associated with a fasting hyperammonemia syndrome with cataracts and vomiting. Then the syndrome was expanded to include a cutis laxa phenotype and more recently it has been associated with spastic paraplegia of dominant or recessive inheritance. Using our baculovirus/insect cell system for producing pure recombinant human P5CS, we introduced dominant and recessive mutations in the enzyme by site-directed mutagenesis, assaying enzyme activity. All the mutations, irrespectively of the type of inheritance they gave, inactivated the catalytic domain of P5CS where they mapped. Gel filtration and modelling evidence strongly suggests that the mutations giving dominant inheritance appear to cause their effects by a negative dominant mechanism. In particular, they are located on the surface of the two domains, in places that in E. coli G5K (a monofuntional tetrameric enzyme) are used in interactions with adjacent domains. Therefore, these dominant mutations may disturb the hexameric enzyme architecture, preventing potential "in vivo" channelling of L-glutamyl-5-phosphate from the G5K domain to a G5PR domain from an adjacent subunit., BFU2014-58229-P(MINECO).
- Published
- 2015
29. ALDH18A1gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism
- Author
-
Panza, Emanuele, primary, Escamilla-Honrubia, Juan M., additional, Marco-Marín, Clara, additional, Gougeard, Nadine, additional, De Michele, Giuseppe, additional, Morra, Vincenzo Brescia, additional, Liguori, Rocco, additional, Salviati, Leonardo, additional, Donati, Maria Alice, additional, Cusano, Roberto, additional, Pippucci, Tommaso, additional, Ravazzolo, Roberto, additional, Németh, Andrea H., additional, Smithson, Sarah, additional, Davies, Sally, additional, Hurst, Jane A., additional, Bordo, Domenico, additional, Rubio, Vicente, additional, and Seri, Marco, additional
- Published
- 2015
- Full Text
- View/download PDF
30. Máquinas moleculares que sintetizan anhidridos fosfóricos
- Author
-
Marco-Marín, Clara, Rubio Zamora, Vicente, Universitat de València - BIOQUÍMICA I BIOLOGIA MOLECULAR, Universitat de València. Departament de Bioquímica i Biologia Molecular, and Rubio, Vicente
- Subjects
none ,Facultat de Biològiques - Abstract
Esta tesis versa sobre el estudio de cuatro enzimas que tienen como función específica la síntesis y liberación del anhidridos fosfóricos, y que son cruciales para la biosíntesis de los aminoácidos ornitina/arginina, prolina, lisina e isoleucina, y para la síntesis microbiana de nucleótidos de pirimidina. Previamente a mi incorporación en el laboratorio, éste habia identificado un plegamiento característico y novedoso común a los enzimas carbamato quinasa (Marina, A. et al., 1999; Ramón-Maiques, S. et al., 2000) y acetilglutamato quinasa (Ramón-Maiques, S. et al., 2002). Ambos enzimas, pertenecen al grupo de la Enzyme Commission EC 2.7.2, transferidores de un fosforilo a un grupo carboxilato, y por tanto, con la misión específica de sintetizar anhidridos mixtos carboxílico-fosfórico, en rutas de biosíntesis de aminoácidos. Carbamato quinasa y acetilglutamato quinasa, pertenecen a la familia estructural aminoácido quinasa (Base de datos PFAM, familia PF00696; http://www.sanger.ac.uk/Software/Pfam), familia que por similitud de secuencia de aminoácidos, incluye además, a los enzimas aspartatoquinasa, glutamato 5-quinasa, UMP quinasa bacteriana y N-acetil L-glutamato sintasa. Dada la similitud de secuencia entre los enzimas de la familia aminoácido quinasa, el laboratorio propuso que el plegamiento de carbamato quinasa y acetilglutamato quinasa iba a ser común al resto de enzimas de la familia y la puesta a prueba experimental de esta hipótesis ha sido uno de los objetivos principales del laboratorio y de mi trabajo. Parte de mi trabajo inicial, se centró en la acetilglutamato quinasa (NAGK), enzima cuya estructura había sido ya determinada a alta resolución (Ramon-Maiques, et al., 2002), por otros miembros del grupo en el que he desarrollado mi trabajo. Mi trabajo en relación con este enzima fue corroborar mediante mutagénesis dirigida, las inferencias funcionales derivadas del estudio estructural previo. Dada la similitud entre acetilglutamato quinasa y aspartoquinasa (AK), otro enzima de la familia amino ácido quinasa, clave en la síntesis de treonina, metionina, lisina e isoleucina, y con gran potencial desde el punto de vista biotecnológico, utilizamos la información estructural de NAGK, para realizar un trabajo de mutagénesis dirigida de aspartoquinasa, cuyos resultados nos permitieron construir un modelo estructural de AK. El tercer enzima que he estudiado, la UMP quinasa, es clave en la síntesis de nucleótidos de pirimidina y presenta la peculiaridad dentro de los enzimas de la familia aminoácido quinasa de sintetizar la formación de un anhidrido fosfórico-fosfórico. Mi trabajo con este enzima se ha centrado en determinar su estructura mediante difracción de rayos X. Por último he estudiado el enzima glutamato 5-quinasa, clave en la síntesis de prolina en microorganismos y plantas, que es tambien clave para la síntesis de ornitina en animales. He determinado la estructura tridimensional de la glutamato 5-quinasa de E. coli mediante difracción de rayos X. El ámbito de estudio con los cuatro enzimas objeto de esta tesis, ha sido siempre el estructural, buscando conectar y asociar rasgos estructurales con comportamiento funcional. El trabajo que he realizado, ha dado lugar a las siguientes publicaciones: Marco-Marín, C. et al (2003). Journal of Molecular Biology (2003) 334, 459-476. Marco-Marín, C. et al (2005). Biochim. Biophys. Acta. (2005) 1747, 271-275. Marco-Marín, C. et al (2005). Journal of Molecular Biology (2005) 352, 438-454. Marco-Marín, C. et al (2007). Journal of Molecular Biology (2007) 367, 1431-1446., This thesis is about four enzymes that synthesize phosphoric anhydrides, and which have key roles on the biosynthetic pathways of ornithine/arginine, proline, lysine and isoleucine, and on the microbial synthesis of pyrimidine nucleotides. A novel and characteristic fold common to the enzymes carbamate kinase (CK) and acetylglutamate kinase (NAGK) had been identified by other members of the laboratory, previously to my incorporation. CK and NAGK belong to the amino acid kinase structural family (PFAM database, PF00696; http://www.sanger.ac.uk/Software/Pfam), that also includes aspartokinase (AK), glutamate 5-kinase, bacterial UMP kinase and N-acetyl L-glutamate synthase. Based on the sequence similarity of these enzymes, the laboratory proposed a common fold for all of them, equivalent to that previously described for CK and NAGK. One of the main objectives of the laboratory and of my work has been to probe this hypothesis experimentally. Initially, I studied NAGK from E. coli and I corroborated by site-directed mutagenesis, functional inferences derived from the previous structural work. The high similitude between NAGK and AK allowed to perform a site-directed mutagenesis study of AK, and to use the results of this study to build a molecular model of the AKIII from E. coli. The third enzyme that I have studied, UMP kinase, is a key enzyme of the pathway of biosynthesis of pyrimidine nucleotides in bacteria, that different to the other enzymes of the amino acid kinase family, synthetizes a phosphoric-phosphoric anhydride. I have determined the 3D-structure of the UMP kinase from Pyrococcus furiosus using X-ray crystallography, and also of the glutamate 5-kinase fom E. coli, which is a key enzyme of the biosynthesic pathway of proline in microorganisms and plants, and also of ornithine in animals. The work of this thesis is included in the following publications: Marco-Marín, C. et al (2003). Journal of Molecular Biology (2003) 334, 459-476. Marco-Marín, C. et al (2005). Biochim. Biophys. Acta. (2005) 1747, 271-275. Marco-Marín, C. et al (2005). Journal of Molecular Biology (2005) 352, 438-454. Marco-Marín, C. et al (2007). Journal of Molecular Biology (2007) 367, 1431-1446, Tesis realizada gracias a una beca FPI de la Generalitat Valenciana e I3P CSIC-Bruker España S.A. y de un contrato con cargo al proyecto BFU2004-05159. El trabajo se ha financiado principalmente con las ayudas BMC2001-2182 y BFU2004-05159 del Plan Nacional de Investigación Científica y Técnica (MCT y MEC). También se ha desarrollado bajo los auspicios del Instituto de Salud Carlos III (MSC; Redes C03/08, G03/54 y FISS PI052838).
- Published
- 2007
31. The site for the allosteric activator GTP of Escherichia coli UMP kinase
- Author
-
Marco-Marín, Clara and Rubio, Vicente
- Published
- 2009
- Full Text
- View/download PDF
32. Correction: The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, Ruiz-Rodriguez, Paula, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jeronimo, Rubio, Vicente, and Marina, Alberto
- Subjects
- *
SARS-CoV-2 , *SUCCESS - Abstract
In the Financial Disclosure, the number for the grant awarded by EPIDNA is incorrect. Reference 1 Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodriguez P, et al. (2022) The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
33. Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine
- Author
-
Martinelli, Diego, primary, Häberle, Johannes, additional, Rubio, Vicente, additional, Giunta, Cecilia, additional, Hausser, Ingrid, additional, Carrozzo, Rosalba, additional, Gougeard, Nadine, additional, Marco-Marín, Clara, additional, Goffredo, Bianca M., additional, Meschini, Maria Chiara, additional, Bevivino, Elsa, additional, Boenzi, Sara, additional, Colafati, Giovanna Stefania, additional, Brancati, Francesco, additional, Baumgartner, Matthias R., additional, and Dionisi-Vici, Carlo, additional
- Published
- 2011
- Full Text
- View/download PDF
34. The site for the allosteric activator GTP of Escherichia coli UMP kinase
- Author
-
Marco-Marín, Clara, primary and Rubio, Vicente, additional
- Published
- 2008
- Full Text
- View/download PDF
35. The crystal structure of the complex of P II and acetylglutamate kinase reveals how P II controls the storage of nitrogen as arginine
- Author
-
Llácer, José L., primary, Contreras, Asunción, additional, Forchhammer, Karl, additional, Marco-Marín, Clara, additional, Gil-Ortiz, Fernando, additional, Maldonado, Rafael, additional, Fita, Ignacio, additional, and Rubio, Vicente, additional
- Published
- 2007
- Full Text
- View/download PDF
36. A Novel Two-domain Architecture Within the Amino Acid Kinase Enzyme Family Revealed by the Crystal Structure of Escherichia coli Glutamate 5-kinase
- Author
-
Marco-Marín, Clara, primary, Gil-Ortiz, Fernando, additional, Pérez-Arellano, Isabel, additional, Cervera, Javier, additional, Fita, Ignacio, additional, and Rubio, Vicente, additional
- Published
- 2007
- Full Text
- View/download PDF
37. The Crystal Structure of Pyrococcus furiosus UMP Kinase Provides Insight into Catalysis and Regulation in Microbial Pyrimidine Nucleotide Biosynthesis
- Author
-
Marco-Marín, Clara, primary, Gil-Ortiz, Fernando, additional, and Rubio, Vicente, additional
- Published
- 2005
- Full Text
- View/download PDF
38. Understanding Carbamoyl Phosphate Synthetase Deficiency: Impact of Clinical Mutations on Enzyme Functionality
- Author
-
Yefimenko, Igor, primary, Fresquet, Vicente, additional, Marco-Marín, Clara, additional, Rubio, Vicente, additional, and Cervera, Javier, additional
- Published
- 2005
- Full Text
- View/download PDF
39. First-time crystallization and preliminary X-ray crystallographic analysis of a bacterial-archaeal type UMP kinase, a key enzyme in microbial pyrimidine biosynthesis
- Author
-
Marco-Marín, Clara, primary, Escamilla-Honrubia, Juan Manuel, additional, and Rubio, Vicente, additional
- Published
- 2005
- Full Text
- View/download PDF
40. The crystal structure of the complex of PII and acetylglutamate kinase reveals how PII controls the storage of nitrogen as arginine.
- Author
-
Llácer, José L., Contreras, Asunción, Forchhammer, Karl, Marco-Marín, Clara, Gil-Ortiz, Fernando, Maldonado, Rafael, Fita, Ignacio, and Rubio, Vicente
- Subjects
CRYSTALS ,FERROMAGNETIC materials ,MAGNETIC domain ,ARGININE ,OLIGOMERS ,CHEMICAL reactions ,GENETIC mutation ,MICROBIAL genetics - Abstract
Photosynthetic organisms can store nitrogen by synthesizing arginine, and, therefore, feedback inhibition of arginine synthesis must be relieved in these organisms when nitrogen is abundant. This relief is accomplished by the binding of the P
II signal transduction protein to acetylglutamate kinase (NAGK), the controlling enzyme of arginine synthesis. Here, we describe the crystal structure of the complex between NAGK and PII of Synechococcus elongatus, at 2.75-A resolution. We prove the physiological relevance of the observed interactions by site-directed mutagenesis and functional studies. The complex consists of two polar PII trimers sandwiching one ring-like hexameric NAGK (a trimer of dimers) with the threefold axes of these molecules aligned. The binding of PII favors a narrow ring conformation of the NAGK hexamer that is associated with arginine sites having low affinity for this inhibitor. Each PII subunit contacts one NAGK subunit only. The contacts map in the inner circumference of the NAGK ring and involve two surfaces of the PII subunit. One surface is on the PII body and interacts with the C-domain of the NAGK subunit, helping widen the arginine site found on the other side of this domain. The other surface is at the distal region of a protruding large loop (T-loop) that presents a novel compact shape. This loop is inserted in the interdomain crevice of the NAGK subunit, contacting mainly the N-domain, and playing key roles in anchoring PII on NAGK, in activating NAGK, and in complex formation regulation by MgATP, ADP, 2-oxoglutarate, and by phosphorylation of serine-49. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
41. Site-directed Mutagenesis of Escherichia coli Acetylglutamate Kinase and Aspartokinase III Probes the Catalytic and Substrate-binding Mechanisms of these Amino Acid Kinase Family Enzymes and Allows Three-dimensional Modelling of Aspartokinase
- Author
-
Marco-Marín, Clara, Ramón-Maiques, Santiago, Tavárez, Sandra, and Rubio, Vicente
- Subjects
- *
MUTAGENESIS , *PROTEIN kinases , *AMINO acids , *MOLECULAR structure - Abstract
We test, using site-directed mutagenesis, predictions based on the X-ray structure of N-acetyl-l-glutamate kinase (NAGK), the paradigm of the amino acid kinase protein family, about the roles of specific residues on substrate binding and catalysis. The mutations K8R and D162E decreased V[sustrate]=∞ 100-fold and 1000-fold, respectively, in agreement with the predictions that K8 catalyzes phosphoryl transfer and D162 organizes the catalytic groups. R66K and N158Q increased selectively
KmAsp three to four orders of magnitude, in agreement with the binding of R66 and N158 to the Cα substituents of NAG. Mutagenesis in parallel of aspartokinase III (AKIII phosphorylates aspartate instead of acetylglutamate), another important amino acid kinase family member of unknown 3-D structure, identified in AKIII two residues, K8 and D202, that appear to play roles similar to those of K8 and D162 of NAGK, and supports the involvement of E119 and R198, similarly to R66 and N158 of NAGK, in the binding of the amino acid substrate, apparently interacting, respectively, with the α-NH3+ and α-COO− of aspartate. These results and an improved alignment of the NAGK and AKIII sequences have guided us into 3-D modelling of the amino acid kinase domain of AKIII using NAGK as template. The model has good stereochemistry and validation parameters. It provides insight into substrate binding and catalysis, agreeing with mutagenesis results with another aspartokinase that were not considered when building the model.AKIII is homodimeric and is inhibited by lysine. Lysine may bind to a regulatory region that is C-terminal to the amino acid kinase domain. We make a C-terminally truncated AKIII (AKIIIt) and show that the C-region is involved in intersubunit interactions, since AKIIIt is found to be monomeric. Further, it is inactive, as demanded if dimer formation is essential for activity. Models for AKIII architecture are proposed that account for these findings. [Copyright &y& Elsevier]- Published
- 2003
- Full Text
- View/download PDF
42. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Ruiz-Rodriguez, Paula, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Bravo, Jeronimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscolla, Mireia, Orozco, Modesto, Llácer, José Luis, Carazo, José-Maria, European Commission, Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Comunidad de Madrid, European Research Council, Instituto de Salud Carlos III, Banco Santander, Generalitat Valenciana, Ginex, Tiziana [0000-0002-5739-8713], Marco-Marín, Clara [0000-0002-8813-3515], Wieczor, Milosz [0000-0003-4990-8629], Mata, Carlos P. [0000-0003-3381-7431], Krieger, James [0000-0001-6194-6244], López-Redondo, Marisa [0000-0002-3328-6821], Francés-Gómez, Clara [0000-0001-7341-3824], Ruiz-Rodríguez, Paula [0000-0003-0727-5974], Melero, Roberto [0000-0001-9467-9381], Sorzano, Carlos Óscar S. [0000-0002-9473-283X], Martínez, Marta [0000-0002-8435-5540], Gougeard, Nadine [0000-0001-7338-7267], Forcada-Nadal, Alicia [0000-0003-0179-4044], Zamora-Caballero, Sara [0000-0003-4717-8845], Gozalbo-Rovira, Roberto [0000-0003-3427-3800], Sanz-Frasquet, Carla [0000-0002-6990-3131], Bravo, Jerónimo [0000-0001-6695-2846], Rubio, Vicente [0000-0001-8124-1196], Marina, Alberto [0000-0002-1334-5273], Geller, Ron [0000-0002-7612-4611], Comas, Iñaki [0000-0001-5504-9408], Gil, Carmen [0000-0002-3882-6081], Coscollá, Mireia [0000-0003-0752-0538], Orozco, Modesto [0000-0002-8608-3278], Llácer, José Luis [0000-0001-5304-1795], Carazo, José M. [0000-0003-0788-8447], Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, López-Redondo, Marisa, Francés-Gómez, Clara, Ruiz-Rodríguez, Paula, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Subjects
0303 health sciences ,03 medical and health sciences ,010402 general chemistry ,01 natural sciences ,3. Good health ,030304 developmental biology ,0104 chemical sciences - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has now reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., This research work was supported by the European Commission–NextGenerationEU through the CSIC Global Health Platform. Additionally, authors would like to acknowledge economic support from the Spanish Ministry of Science and Innovation through Grants: PID2019-104757RB-I00 funded by MCIN/AEI/ 10.13039/501100011033, RTI2018-094399-A-I00, and “ERDF A way of making Europe”, by the “European Union”, Grant SEV 2017-0712 funded by MCIN/AEI /10.13039/501100011033, the “Comunidad Autónoma de Madrid" through Grant: S2017/BMD3817, and the European Union (EU) and Horizon 2020 through grants: Marie-Curie Fellowship EnLaCES (MSCA IF 2020, Proposal: 101024130) (to JK), HighResCells (ERC - 2018 - SyG, Proposal: 810057), and iNEXT-Discovery (Proposal: 871037). AM, VR, JB and JLL are funded by CIBERER-ISCIII (proposal: COV20/00437), Fondo Supera COVID-19 (proposal: CSICCOVID19-082), Banco Santander (Proposal: BlockAce), and CSIC PTI Salud Global (Proposal: 202080E110). VR is funded by the Spanish Ministry of Science and Innovation through Grant PID2020-120322RB-C21. IC is funded by project PID2019-104477RB-100, Fondo COVID COV20/00140 and ERC CoG 101001038. MC is funded by the RyC program from the Spanish Ministry of Science and Innovation, the Generalitat Valenciana (SEJI/2019/011).
- Full Text
- View/download PDF
43. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, The IBV-Covid19-Pipeline, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, Carazo, José M., European Commission, Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia e Innovación (España), Generalitat Valenciana, Comunidad de Madrid, Banco Santander, Instituto de Salud Carlos III, Ginex, Tiziana [0000-0002-5739-8713], Marco-Marín, Clara [0000-0002-8813-3515], Wieczor, Milosz [0000-0003-4990-8629], Mata, Carlos P. [0000-0003-3381-7431], Krieger, James [0000-0001-6194-6244], Ruiz-Rodríguez, Paula [0000-0003-0727-5974], López-Redondo, Marisa [0000-0002-3328-6821], Francés-Gómez, Clara [0000-0001-7341-3824], Melero, Roberto [0000-0001-9467-9381], Sorzano, Carlos Óscar S. [0000-0002-9473-283X], Martínez, Marta [0000-0002-8435-5540], Gougeard, Nadine [0000-0001-7338-7267], Forcada-Nadal, Alicia [0000-0003-0179-4044], Zamora-Caballero, Sara [0000-0003-4717-8845], Gozalbo-Rovira, Roberto [0000-0003-3427-3800], Sanz-Frasquet, Carla [0000-0002-6990-3131], Arranz, Rocío [0000-0001-5321-0915], Bravo, Jerónimo [0000-0001-6695-2846], Rubio, Vicente [0000-0001-8124-1196], Marina, Alberto [0000-0002-1334-5273], Geller, Ron [0000-0002-7612-4611], Comas, Iñaki [0000-0001-5504-9408], Gil, Carmen [0000-0002-3882-6081], Coscollá, Mireia [0000-0003-0752-0538], Orozco, Modesto [0000-0002-8608-3278], Llácer, José Luis [0000-0001-5304-1795], Carazo, José M. [0000-0003-0788-8447], Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Subjects
Vaccines ,SARS-CoV-2 ,Mutació (Biologia) ,Immunology ,COVID-19 ,Peptidyl-Dipeptidase A ,Mutation (Biology) ,Vacunes ,Infections ,Microbiology ,Infeccions ,Virology ,Mutation ,Spike Glycoprotein, Coronavirus ,Genetics ,Humans ,Receptors, Virus ,Parasitology ,Angiotensin-Converting Enzyme 2 ,Genetic Background ,Molecular Biology ,Protein Binding - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., In this research work, PRR and TG were supported by salaries from the European Commission–NextGenerationEU through the CSIC Global Health Platform established by EU Council Regulation 2020/2094. The authors would like to acknowledge economic support from: (a) the Spanish Ministry of Science and Innovation through grants: SEV-2017-0712 funded by MCIN/AEI/10.13039/501100011033 (CPM, JK, RM, COSS, MM, RA, JMC); 116880GB-I00 (JLL) and 120322RB-C21 (VR) funded within PID 2020; PID2019-104757RB-I00 funded by MCIN/AEI/10.13039/501100011033/ and “ERDF A way of making Europe”, by the “European Union” (JMC, COSS, RM, MM, CPM) and 104477RB-100 (IC) funded within PID 2019; RYC-2015-18213 (salary of MC) and RYC-2015-17517 (salary of RG) funded by the Ramon y Cajal fellowship program; RTI2018-094399-A-I00 (JMC, COSS, RM, CPM, MC) funded within the Retos Investigación program; the CRIOMECORR project funded as ESFRI-2019-01-CSIC-16; (b) the Horizon 2020 program through Marie Skłodowska-Curie Individual Fellowships EnLaCES (Proposal 101024130, salary of JK) and EPIDNA (Grant ID: 894498, salary of MW); (c) the European Research Council (ERC) through grants: ERC-2018-SyG-810057 HighResCells funded within the EXCELLENT SCIENCE program (JMC, MM, COSS, salary of RM), Grant 871037 iNEXT DISCOVERY (JMC, MM, COSS) and grant CoG-101001038 funded within the Consolidator Grants program (IC); (d) Generalitat Valenciana through grants: SEJI/2019/011 (MC) and SEJI/2019/030 (JLL); (e) Comunidad de Madrid through grant: S2017/BMD-3817 (JMC); (f) Santander Bank through grant: CSIC-COVID19-082 (AM, VR, JB, JLL, RG) funded through the Fondo Supera Covid-19; (g) Instituto de Salud Carlos III through grants: COV20/00437 (AM, VR, JB, JLL) and COV20/00140 (IC), both funded through the Fondos Covid-19 initiative; (h) Spanish National Research Council through grant: 202080E110 funded within the PTI Salud Global initiative (AM, VR, JB, JLL, RG).
- Full Text
- View/download PDF
44. A novel TRMT5 mutation causes a complex inherited neuropathy syndrome: The role of nerve pathology in defining a demyelinating neuropathy
- Author
-
Herminia Argente‐Escrig, Juan J. Vílchez, Marina Frasquet, Nuria Muelas, Inmaculada Azorín, Roger Vílchez, Elvira Millet‐Sancho, Inmaculada Pitarch, Miguel Tomás‐Vila, Juan F. Vázquez‐Costa, Fernando Mas‐Estellés, Clara Marco‐Marín, Carmen Espinós, Pablo Serrano‐Lorenzo, Miguel A. Martin, Vincenzo Lupo, Teresa Sevilla, Fundación Isabel Gemio, Generalitat Valenciana, Instituto de Salud Carlos III, European Commission, Marco-Marín, Clara [0000-0002-8813-3515], and Marco-Marín, Clara
- Subjects
Mitochondrial disorders ,tRNA Methyltransferases ,Mitochondrial Diseases ,Histology ,Inherited neuropathy ,Mitochondrial neuropathies ,Peripheral Nervous System Diseases ,Syndrome ,Pathology and Forensic Medicine ,Phenotype ,mitochondrial disorders ,RNA, Transfer ,Neurology ,inherited neuropathy ,TRMT5 ,Physiology (medical) ,Mutation ,Humans ,Neurology (clinical) ,mitochondrial neuropathies - Abstract
14 páginas, 4 figuras, 3 tablas, Aims: We aim to present data obtained from three patients belonging to three unrelated families with an infantile onset demyelinating neuropathy associated to somatic and neurodevelopmental delay and to describe the underlying genetic changes. Methods: We performed whole-exome sequencing on genomic DNA from the patients and their parents and reviewed the clinical, muscle and nerve data, the serial neurophysiological studies, brain and muscle MRIs, as well as the respiratory chain complex activity in the muscle of the three index patients. Computer modelling was used to characterise the new missense variant detected. Results: All three patients had a short stature, delayed motor milestone acquisition, intellectual disability and cerebellar abnormalities associated with a severe demyelinating neuropathy, with distinct morphological features. Despite the proliferation of giant mitochondria, the mitochondrial respiratory chain complex activity in skeletal muscle was normal, except in one patient in whom there was a mild decrease in complex I enzyme activity. All three patients carried the same two compound heterozygous variants of the TRMT5 (tRNA Methyltransferase 5) gene, one known pathogenic frameshift mutation [c.312_315del (p.Ile105Serfs*4)] and a second rare missense change [c.665 T > C (p.Ile222Thr)]. TRMT5 is a nuclear-encoded protein involved in the post-transcriptional maturation of mitochondrial tRNA. Computer modelling of the human TRMT5 protein structure suggests that the rare p.Ile222Thr mutation could affect the stability of tRNA binding. Conclusions: Our study expands the phenotype of mitochondrial disorders caused by TRTM5 mutations and defines a new form of recessive demyelinating peripheral neuropathy., Fundación Isabel Gemio; Generalitat Valenciana, Grant/Award Number:PROMETEO/2018/13; Fondo Europeo deDesarrollo Regional (FEDER); Instituto deSalud Carlos III, Grant/Award Numbers:PI19/01178, PI18/01374, PI16/00403
- Published
- 2022
45. Mutations, Genes, and Phenotypes Related to Movement Disorders and Ataxias
- Author
-
Dolores Martínez-Rubio, Isabel Hinarejos, Paula Sancho, Nerea Gorría-Redondo, Raquel Bernadó-Fonz, Cristina Tello, Clara Marco-Marín, Itxaso Martí-Carrera, María Jesús Martínez-González, Ainhoa García-Ribes, Raquel Baviera-Muñoz, Isabel Sastre-Bataller, Irene Martínez-Torres, Anna Duat-Rodríguez, Patrícia Janeiro, Esther Moreno, Leticia Pías-Peleteiro, Mar O’Callaghan Gordo, Ángeles Ruiz-Gómez, Esteban Muñoz, Maria Josep Martí, Ana Sánchez-Monteagudo, Candela Fuster, Amparo Andrés-Bordería, Roser Maria Pons, Silvia Jesús-Maestre, Pablo Mir, Vincenzo Lupo, Belén Pérez-Dueñas, Alejandra Darling, Sergio Aguilera-Albesa, Carmen Espinós, Institut Català de la Salut, [Martínez-Rubio D, Hinarejos I] Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. Joint Unit CIPF-IIS La Fe Rare Diseases, Valencia, Spain. [Sancho P, Tello C] Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. [Gorría-Redondo N, Bernadó-Fonz R] Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario de Navarra, Navarrabiomed, Pamplona, Spain. [Pérez-Dueñas B] Servei de Neurologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Instituto de Salud Carlos III, European Commission, Fundació La Marató de TV3, Generalitat Valenciana, Ministerio de Educación, Cultura y Deporte (España), Fundació per Amor a L'Art, Marco-Marín, Clara [0000-0002-8813-3515], and Marco-Marín, Clara
- Subjects
Iron ,Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES] ,Kinesins ,Catalysis ,Atàxia - Aspectes genètics ,Inorganic Chemistry ,cerebellar atrophy ,gene panel ,Other subheadings::Other subheadings::/genetics [Other subheadings] ,Humans ,movement disorders ,ataxia ,neurodegeneration with brain iron accumulation (NBIA) ,exome sequencing ,Physical and Theoretical Chemistry ,Molecular Biology ,fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS] ,Spectroscopy ,Movement Disorders ,Otros calificadores::Otros calificadores::/genética [Otros calificadores] ,Organic Chemistry ,Brain ,Neurodegenerative Diseases ,General Medicine ,Computer Science Applications ,Fenotip ,Phosphotransferases (Alcohol Group Acceptor) ,Anomalies cromosòmiques ,Phenotype ,enfermedades del sistema nervioso::manifestaciones neurológicas::discinesias::ataxia [ENFERMEDADES] ,Mutation ,Genetic Phenomena::Phenotype [PHENOMENA AND PROCESSES] ,Ataxia ,fenómenos genéticos::fenotipo [FENÓMENOS Y PROCESOS] ,Nervous System Diseases::Neurologic Manifestations::Dyskinesias::Ataxia [DISEASES] - Abstract
26 páginas, 4 figuras, 3 tablas, Our clinical series comprises 124 patients with movement disorders (MDs) and/or ataxia with cerebellar atrophy (CA), many of them showing signs of neurodegeneration with brain iron accumulation (NBIA). Ten NBIA genes are accepted, although isolated cases compatible with abnormal brain iron deposits are known. The patients were evaluated using standardised clinical assessments of ataxia and MDs. First, NBIA genes were analysed by Sanger sequencing and 59 patients achieved a diagnosis, including the detection of the founder mutation PANK2 p.T528M in Romani people. Then, we used a custom panel MovDisord and/or exome sequencing; 29 cases were solved with a great genetic heterogeneity (34 different mutations in 23 genes). Three patients presented brain iron deposits with Fe-sensitive MRI sequences and mutations in FBXO7, GLB1, and KIF1A, suggesting an NBIA-like phenotype. Eleven patients showed very early-onset ataxia and CA with cortical hyperintensities caused by mutations in ITPR1, KIF1A, SPTBN2, PLA2G6, PMPCA, and PRDX3. The novel variants were investigated by structural modelling, luciferase analysis, transcript/minigenes studies, or immunofluorescence assays. Our findings expand the phenotypes and the genetics of MDs and ataxias with early-onset CA and cortical hyperintensities and highlight that the abnormal brain iron accumulation or early cerebellar gliosis may resembling an NBIA phenotype., This work was supported by the Instituto de Salud Carlos III (ISCIII)—Subdirección General de Evaluación y Fomento de la Investigación within the framework of the National R + D+I Plan co-funded with European Regional Development Funds (ERDF) [Grants PI18/00147 and PI21/00103 to CE]; the Fundació La Marató TV3 [Grants 20143130 and 20143131 to BPD and CE]; and by the Generalitat Valenciana [Grant PROMETEO/2018/135 to CE]. Part of the equipment employed in this work was funded by Generalitat Valenciana and co-financed with ERDF (OP ERDF of Comunitat Valenciana 2014–2020). PS had an FPU-PhD fellowship funded by the Spanish Ministry of Education, Culture and Sport [FPU15/00964]. IH has a PFIS-PhD fellowship [FI19/00072]. ASM has a contract funded by the Spanish Foundation Per Amor a l’Art (FPAA)
- Published
- 2022
46. A newly distal hereditary motor neuropathy caused by a rare AIFM1 mutation
- Author
-
Erwin Knecht, Antonio Collado, Vincenzo Lupo, Cristina Domínguez-González, Ana Sánchez-Monteagudo, Paula Sancho, Carmen Espinós, Clara Marco-Marín, Ana Camacho, Instituto de Salud Carlos III, Ministerio de Educación, Cultura y Deporte (España), Centro de Investigación Biomédica en Red Enfermedades Raras (España), Marco-Marín, Clara, and Marco-Marín, Clara [0000-0002-8813-3515]
- Subjects
Male ,0301 basic medicine ,Proband ,Gene panel ,AIFM1 ,In silico ,Biology ,medicine.disease_cause ,Muscular Atrophy, Spinal ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Genes, X-Linked ,Genetics ,medicine ,Humans ,Gene ,health care economics and organizations ,Genetics (clinical) ,Mutation ,Infant ,Proteins ,Phenotype ,Human genetics ,Pedigree ,Mitochondrial disorder ,Apoptosis inducing factor ,030104 developmental biology ,Cancer research ,Apoptosis-inducing factor ,Female ,Inherited peripheral neuropathies ,030217 neurology & neurosurgery - Abstract
6 Páges, 1 Figure, 1 Table. The online version of this article (https://doi.org/10.1007/s10048-017-0524-6) contains supplementary material, which is available to authorized users., In two siblings, who suffer from an early childhood-onset axonal polyneuropathy with exclusive involvement of motor fibers, the c.629T>C (p.F210S) mutation was identified in the X-linked AIFM1 gene, which encodes for the apoptosis-inducing factor (AIF). The mutation was predicted as deleterious, according to in silico analysis. A decreased expression of the AIF protein, altered cellular morphology, and a fragmented mitochondrial network were observed in the proband's fibroblasts. This new form of motor neuropathy expands the phenotypic spectrum of AIFM1 mutations and therefore, the AIFM1 gene should be considered in the diagnosis of hereditary motor neuropathies., This project was funded by the Instituto de Salud Carlos III (ISCIII)–FEDER (grant nos. PI12/00453 and PI15/00187). P.S. has a FPU grant funded by the Ministerio de Educación, Cultura y Deporte (grant no. FPU15/00964). A.S.M. has a grant funded by the Fundació per amor a l’art (FPAA). C.E. has a BMiguel Servet^ contract funded by the ISCIII and Centro de Investigación Príncipe Felipe (CIPF) (grant no. CPII14/00002). The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) is an initiative from the ISCIII.
- Published
- 2017
47. ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism
- Author
-
Giuseppe De Michele, Vicente Rubio, Domenico Bordo, Andrea H. Németh, Sally J. Davies, Jane A. Hurst, Roberto Cusano, Nadine Gougeard, Emanuele Panza, Juan Manuel Escamilla-Honrubia, Leonardo Salviati, Vincenzo Brescia Morra, Clara Marco-Marín, Marco Seri, Sarah F. Smithson, Rocco Liguori, Tommaso Pippucci, Maria Alice Donati, Roberto Ravazzolo, Panza, Emanuele, Escamilla-Honrubia, Juan M, Marco-Marín, Clara, Gougeard, Nadine, De Michele, Giuseppe, Brescia Morra, Vincenzo, Liguori, Rocco, Salviati, Leonardo, Donati, Maria Alice, Cusano, Roberto, Pippucci, Tommaso, Ravazzolo, Roberto, Németh, Andrea H, Smithson, Sarah, Davies, Sally, Hurst, Jane A, Bordo, Domenico, Rubio, Vicente, Seri, Marco, Ministerio de Economía y Competitividad (España), Generalitat Valenciana, Centro de Investigación Biomédica en Red Enfermedades Raras (España), Escamilla-Honrubia, Juan Manuel, Escamilla Honrubia, Juan M, Marco Marín, Clara, DE MICHELE, Giuseppe, BRESCIA MORRA, Vincenzo, Rubio, Vicente [0000-0001-8124-1196], and Escamilla-Honrubia, Juan Manuel [0000-0003-0154-6569]
- Subjects
0301 basic medicine ,Male ,Ornithine ,Candidate gene ,Mutagenesis (molecular biology technique) ,Biology ,Gene mutation ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Congenital Bilateral Cataracts ,medicine ,Humans ,Spastic Paraplegia ,Gene ,Loss function ,Genetics ,Mutation ,Spastic Paraplegia, Hereditary ,Medicine (all) ,Aldehyde Dehydrogenase ,Phenotype ,030104 developmental biology ,Hereditary ,Female ,Neurology (clinical) ,030217 neurology & neurosurgery ,Human - Abstract
8 páginas, 4 figuras, 1 tabla, Supported by Grants from the Comitato Telethon Fondazione Onlus, the Amministrazione Autonoma dei Monopoli di Stato, the city of Gubbio, Italy (grant numbers GGP06209 and GGP10121), the Italian Ministry of Health (‘Identification of tumor biomarkers through a biologydriven integrated approach’), and the Spanish and the Valencian Governments (grants BFU2011-30407 and Prometeo II/2014/029, respectively). NG holds a contract of CIBERER.
- Published
- 2016
48. Protein misfolding and clearance in the pathogenesis of a new infantile onset ataxia caused by mutations in PRDX3
- Author
-
Dolores Martínez-Rubio, Ángela Rodríguez-Prieto, Paula Sancho, Carmen Navarro-González, Nerea Gorría-Redondo, Javier Miquel-Leal, Clara Marco-Marín, Alison Jenkins, Mario Soriano-Navarro, Alberto Hernández, Belén Pérez-Dueñas, Pietro Fazzari, Sergio Aguilera-Albesa, Carmen Espinós, Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Competitividad (España), Fundació La Marató de TV3, Generalitat Valenciana, Ministerio de Ciencia e Innovación (España), Marco-Marín, Clara, Institut Català de la Salut, [Martínez-Rubio D] Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. Joint Unit CIPF-IIS La Fe Rare Diseases, Valencia, Spain. [Rodríguez-Prieto Á, Navarro-González C, Miquel-Leal J] Cortical Circuits in Health and Disease Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. [Sancho P] Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain. [Gorría-Redondo N] Pediatric Neurology Unit, Department of Pediatrics, Complejo Hospitalario de Navarra, Navarrabiomed, Pamplona, Spain. [Pérez-Dueñas B] Servei de Neurologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Pediatria ,Peroxiredoxin III ,Cerebel - Degeneració ,Cerebellar Ataxia ,Otros calificadores::Otros calificadores::/genética [Otros calificadores] ,aminoácidos, péptidos y proteínas::proteínas::proteínas mitocondriales [COMPUESTOS QUÍMICOS Y DROGAS] ,General Medicine ,Atàxia - Aspectes genètics ,Mitochondrial Proteins ,Mice ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades cerebelosas::degeneraciones espinocerebelosas [ENFERMEDADES] ,enfermedades del sistema nervioso::manifestaciones neurológicas::discinesias::ataxia [ENFERMEDADES] ,Amino Acids, Peptides, and Proteins::Proteins::Mitochondrial Proteins [CHEMICALS AND DRUGS] ,Mutation ,Other subheadings::Other subheadings::/genetics [Other subheadings] ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebellar Diseases::Spinocerebellar Degenerations [DISEASES] ,Genetics ,Humans ,Animals ,Ataxia ,Molecular Biology ,Genetics (clinical) ,Nervous System Diseases::Neurologic Manifestations::Dyskinesias::Ataxia [DISEASES] ,HeLa Cells ,Spinocerebellar Degenerations - Abstract
17 páginas, 8 figuras, Peroxiredoxin 3 (PRDX3) encodes a mitochondrial antioxidant protein, which is essential for the control of reactive oxygen species homeostasis. So far, PRDX3 mutations are involved in mild-to-moderate progressive juvenile onset cerebellar ataxia. We aimed to unravel the molecular bases underlying the disease in an infant suffering from cerebellar ataxia that started at 19 months old and presented severe cerebellar atrophy and peripheral neuropathy early in the course of disease. By whole exome sequencing, we identified a novel homozygous mutation, PRDX3 p.D163E, which impaired the mitochondrial ROS defense system. In mouse primary cortical neurons, the exogenous expression of PRDX3 p.D163E was reduced and triggered alterations in neurite morphology and in mitochondria. Mitochondrial computational parameters showed that p.D163E led to serious mitochondrial alterations. In transfected HeLa cells expressing the mutation, mitochondria accumulation was detected by correlative light electron microscopy. Mitochondrial morphology showed severe changes, including extremely damaged outer and inner membranes with a notable cristae disorganization. Moreover, spherical structures compatible with lipid droplets were identified, which can be associated with a generalized response to stress and can be involved in the removal of unfolded proteins. In the patient's fibroblasts, PRDX3 expression was nearly absent. The biochemical analysis suggested that the mutation p.D163E would result in an unstable structure tending to form aggregates that trigger unfolded protein responses via mitochondria and endoplasmic reticulum. Altogether, our findings broaden the clinical spectrum of the recently described PRDX3-associated neurodegeneration and provide new insight into the pathological mechanisms underlying this new form of cerebellar ataxia., The Instituto de Salud Carlos III (ISCIII)—Subdirección General de Evaluación y Fomento de la Investigación within the framework of the National R + D + I Plan cofunded with European Regional Development Funds (ERDF) (grants PI18/00147 and PI21/00103 to C.E.); the Spanish Ministry of Economy and Competitiveness (grant SAF2017-89020-R to P.F.); the Fundació La Marató TV3 (grants 20143130 and 20143131 to B.P.-D. and C.E.) and the Generalitat Valenciana (grant PROMETEO/2018/135 to C.E.). Part of the equipment employed in this work was funded by Generalitat Valenciana and co-financed with ERDF (OP ERDF of Comunitat Valenciana 2014-2020). P.F. and A.R.-P. are supported by the Spanish Ministry of Science and Innovation (grants RyC-2014-16410 to P.F. and PRE2018-083562 to A.R.-P.).
- Published
- 2022
49. The P II -NAGK-PipX-NtcA Regulatory Axis of Cyanobacteria: A Tale of Changing Partners, Allosteric Effectors and Non-covalent Interactions.
- Author
-
Forcada-Nadal A, Llácer JL, Contreras A, Marco-Marín C, and Rubio V
- Abstract
P
II , a homotrimeric very ancient and highly widespread (bacteria, archaea, plants) key sensor-transducer protein, conveys signals of abundance or poorness of carbon, energy and usable nitrogen, converting these signals into changes in the activities of channels, enzymes, or of gene expression. PII sensing is mediated by the PII allosteric effectors ATP, ADP (and, in some organisms, AMP), 2-oxoglutarate (2OG; it reflects carbon abundance and nitrogen scarcity) and, in many plants, L-glutamine. Cyanobacteria have been crucial for clarification of the structural bases of PII function and regulation. They are the subject of this review because the information gathered on them provides an overall structure-based view of a PII regulatory network. Studies on these organisms yielded a first structure of a PII complex with an enzyme, (N-acetyl-Lglutamate kinase, NAGK), deciphering how PII can cause enzyme activation, and how it promotes nitrogen stockpiling as arginine in cyanobacteria and plants. They have also revealed the first clear-cut mechanism by which PII can control gene expression. A small adaptor protein, PipX, is sequestered by PII when nitrogen is abundant and is released when is scarce, swapping partner by binding to the 2OG-activated transcriptional regulator NtcA, co-activating it. The structures of PII -NAGK, PII -PipX, PipX alone, of NtcA in inactive and 2OG-activated forms and as NtcA-2OG-PipX complex, explain structurally PII regulatory functions and reveal the changing shapes and interactions of the T-loops of PII depending on the partner and on the allosteric effectors bound to PII . Cyanobacterial studies have also revealed that in the PII -PipX complex PipX binds an additional transcriptional factor, PlmA, thus possibly expanding PipX roles beyond NtcA-dependency. Further exploration of these roles has revealed a functional interaction of PipX with PipY, a pyridoxal-phosphate (PLP) protein involved in PLP homeostasis whose mutations in the human ortholog cause epilepsy. Knowledge of cellular levels of the different components of this PII -PipX regulatory network and of KD values for some of the complexes provides the basic background for gross modeling of the system at high and low nitrogen abundance. The cyanobacterial network can guide searches for analogous components in other organisms, particularly of PipX functional analogs.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.